Aktienanalyse zu Immunitybio Inc (IBRX)IBRXImmunitybio Inc

ImmunityBio, Inc. is a biotechnology company focused on developing and commercializing immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the goal of restoring immune function and generating lasting immunological memory in patients. The Cancer BioShield platform is designed to stimulate critical lymphocytes, including natural killer (NK) cells, cytotoxic T cells, and memory T cells via its IL-15 receptor agonist, ANKTIVA. The Cancer BioShield platform is anchored by this antibody-cytokine fusion protein and is complemented by a portfolio that includes adenovirus-vectored vaccines, allogeneic (off-the-shelf) and autologous NK-cell therapies, and additional immunomodulators intended to promote immunogenic cell death and support durable immune responses while potentially reducing reliance on high-dose chemo-radiation therapy. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

ImmunityBio Inc (IBRX) is a good buy right now due to its current price of $8.05, which is significantly lower than the analyst price target of $12, indicating a potential upside of 49%. Additionally, the stock has shown a remarkable year-to-date change of +298.51%, reflecting strong investor interest and momentum. The main risk is the negative net income, which reached -632,782,000 USD in Q1 2026, highlighting ongoing financial challenges that investors should monitor closely.